Efficacy of Ponatinib versus Earlier-Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia

Complete molecular response (CMR) and overall survival (OS) in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) treated with front-line chemotherapy plus ponatinib versus earlier-generation tyrosine kinase inhibitors (TKIs) were compared in a meta-analysis and meta-regression. Patients treated with front-line ponatinib versus earlier-generation treatments were more likely to achieve CMR and had higher rates of 3-year OS.

Source: Clinical Lymphoma, Myeloma and Leukemia - February 17, 2018 Category: Hematology Authors: Elias Jabbour, Maral DerSarkissian, Mei Sheng Duh, Nora McCormick, Wendy Y. Cheng, Lisa J. McGarry, Ariadne Souroutzidis, Hui Huang, Susan O ’Brien, Farhad Ravandi, Hagop M. Kantarjian Tags: Original Study Source Type: research